New hope for patients with less common breast cancer
Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15-20 percent of all breast cancer cases.
HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years.
"Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP.
The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug.
Smart bomb
This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney. "Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much."
Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab.
In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported.
44 percent risk reduction
At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 percent compared to standard care. Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 percent in the THP group.
Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in.
Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimising how long patients remain on the treatment, particularly those showing complete remission.
"This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
2 hours ago
- Indian Express
Bengal reports 58 active Covid-19 cases in last 24 hours; 10-month-old child in ICU
On Saturday, West Bengal recorded 58 more Covid-19 cases, taking the total number of active cases in the state to 622. With this, the state became the fourth-highest Covid-positive state in the country, only after Kerala, Gujarat, and Delhi. According to the health department, a two-year-old child and a 10-month-old toddler have been admitted to a private hospital, off EM Bypass. Sources said the baby with breathing issues is in the ICU in the pediatric ward of the hospital with breathing issues. Covid-testing counters have also been opened at the Calcutta Medical College and Hospital. Sources in the health department stated that a report has been sent to the Central health department informing the steps taken by the state, the current figures of hospital admissions and the condition of patients. The number of active cases in Kolkata city has seen a sharp rise by the end of May, as per records. At the beginning of May, the city had only one positive case. There has also been one death in the state due to Covid. Meanwhile, a war of wards has broken out after Leader of Opposition Suvendhu Adhikari on Friday accused the state government of hiding the actual Covid patients in the state. 'The way dengue data is being withheld, the Covid situation is also being obscured. This is a clear attempt to hide the truth from the people. This is not merely an administrative lapse; it reflects a serious disregard for the health and safety of ordinary citizens,' he said. However, Minister of State for Health Chandrima Bhattacharya refuted Adhikari's allegation. Bhattacharya said that the health sector is a state government issue. 'We are not interested in what someone is saying The Centre is aware of what we are doing. A meeting was held a few days ago by the Central Government which I had attended. Several issues were discussed. The Opposition leader may not know this. The Centre heaped praise after listening to what steps the Mamata Banerjee government has taken to check various diseases.' Though the state health department is yet to issue a health advisory, the Kolkata Corporation has decided to raise awareness on precautionary measures. According to sources, the Kolkata Municipal Corporation (KMC) will be putting up banners in all its health units across the city urging people to wash their hands, wear masks, and maintain social distancing. The health workers in all wards have been directed to collect information regarding Covid symptoms, besides usual exercise of data collection of malaria or dengue. They have been advised to isolate any person if found with influenza-like symptoms or severe acute respiratory symptoms (SARI). With the rising cases, the health department said two isolation wards have been kept ready at ID Hospital in case the number spikes.
The Hindu
11 hours ago
- The Hindu
West Bengal LoP Suvendu Adhikari accuses State of ‘suppressing' fresh Covid data
Leader of Opposition of the West Bengal Legislative Assembly and Bharatiya Janata Party (BJP) legislator Suvendu Adhikari on Friday accused the West Bengal government of keeping the State's Covid bulletin 'defunct' in a bid to 'suppress' the data on fresh Covid-positive cases in West Bengal. 'The State health department's Covid portal has been kept non-functioning to ensure the real number of Covid-positive cases does not get recorded there. The real Covid data is being suppressed in the same way that figures of dengue cases were suppressed,' Mr Adhikari said. Notably, official Covid bulletins have not been released on the State Health Department website since January 28, 2023. The bulletins, which were being uploaded almost daily since February 2020, carried facts and figures with respect to active Covid cases, fatalities, and recoveries in the State. The lack of updated data on fresh Covid cases on the West Bengal Health Department website assumes significance in the wake of a developing Covid surge in the country, where several positive cases are being recorded daily across States. A total of 55 people have died from Covid-related causes this year, according to the Covid dashboard operated by the Union Ministry of Health and Family Welfare. In the Union Health Ministry's Covid dashboard, West Bengal recorded the third-highest increase in Covid-positive cases (58) among the States between June 5 and June 6, accounting for a total of 596 active cases in the State. Meanwhile, 91 people were cured and discharged on June 6, amounting to a total of 218 cured Covid cases so far this year. So far, one person has died from Covid-related causes in West Bengal this year, according to the Union Ministry of Health and Family Welfare data. On Friday, LoP Mr Adhikari also claimed to have accessed the State's 'accurate' district-wise Covid data. 'In Malda, for example, if 10 people are being tested for Covid, nine are being found to be positive,' he added. He further alleged that similar 'data suppression' was seen during the dengue wave. 'Doctors were scared of writing dengue as a diagnosis, in fear of transfer or torture. Now, the cases cannot be suppressed, so the government has stopped updating the data on the portal,' Mr Adhikari said. On being asked the source of the data he cited, the LoP said that the West Bengal administration does not just comprise 'Mamata Banerjee's people' but also supporters of the saffron party. Meanwhile, Trinamool Congress leader Kunal Ghosh opposed Mr Adhikari's accusations, saying that the State government is monitoring the situation and taking necessary steps. 'People have been told to stay alert. The State is making necessary system-based arrangements. However, the BJP has a habit of using fearmongering as a political tool. They should focus on the Covid situation in saffron-ruled States. The situation is in control in West Bengal,' Mr Ghosh said. Rally for 'Nari Samman' On Friday, Mr Adhikari also announced that he will lead a 'Nari Samman Yatra' (rally for women's honour) on June 9 in Bolpur in West Bengal's Birbhum district. Recently, Trinamool Congress leader Anubrata Mondal was accused of verbally abusing and threatening the Officer-in-Charge of Bolpur police station and his female family members after the alleged audio of a phone call between Mr Mondal and the police officer went viral.
The Hindu
21 hours ago
- The Hindu
New hope for patients with less common breast cancer
Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15-20 percent of all breast cancer cases. HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. "Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. Smart bomb This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney. "Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much." Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported. 44 percent risk reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 percent compared to standard care. Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 percent in the THP group. Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimising how long patients remain on the treatment, particularly those showing complete remission. "This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study
